Author: admin

The lack of compliance with the guidelines set by European guidelines of hypertension interferes with the proper treatment of hypertensive patients.

|

the lack of compliance with the guidelines set by the European hypertension guidelines interfere with the proper treatment of the hypertensive. patients

according to the findings of the survey SHARE, which publishes Journal of Hypertension.



-poll, in which participated 2.629 doctors in primary care and specialists from all over Europe, part of HypertensionCare, the initiative of Daiichi Sankyo that combines medicines, services and knowledge to hypertension.



Madrid, July 2011.-health professionals do not treat in a systematic manner their patients according to the targets posed by European societies hypertension guidelines hypertension and Cardiology (ESH-ESC, according to its English acronym). This is one of the main findings of the survey SHARE (Supporting Hypertension Awareness & Research Europe-wide, i.e. support for awareness-raising and research on hypertension in Europe), whose results are published in Journal of Hypertension.

the lack of monitoring by doctors of the guidelines set by the European guidelines is one of the factors that contribute to a greater extent to increase charges associated with hipertensión1, suffering from more than one billion people and disease causing 7.6 million deaths each year. Only in Spain, it is estimated that they suffer from high blood pressure more than 13 million people. If it is not treated properly, this disease can cause serious cardiovascular complications among the heart attack and stroke. Also, the lack of control of hypertension is one of the main factors of health spending and only in Europe is estimated to cardiovascular health cost of more than 190,000 million euros for the year.



main results . 

SHARE survey has counted with the participation of 2.629 primary care physicians and specialists throughout Europe. according to the results, 90% of respondents say that they do not take measures against high blood pressure of patients so far that the diastolic blood pressure levels exceed levels recommended by guidelines, a figure that rises to 95 per cent of respondents in the case of systolic blood pressure.

in spite of which 82% European health professionals consider that the objectives of blood pressure of 140/90 mmHg marked by guides ESH-ESC are “ correct broadly ”, the average blood pressure which are beginning to see grounds for concern-ing is 149/92 mmHgpretty on top of dictating the guides. Moreover, the interviewed doctors consider blood pressure must achieve an average of 168/100 mmHg to feel who must take immediate action.

“ any patient with blood pressure greater than 140/90 mmHg needs to be addressed properly to reduce his level of hypertension and the risk of cardiovascular disease. To delay treatment, doctors are potentially increasing the possibility of their patients to undergo a cardiovascular event ”, says Professor Roland Schmieder, head of competition unit of clinical research on hypertension and Vascular Medicine of the University Hospital of Erlangen and Professor of internal medicine, Nephrology and hypertensionGermany, and a member of the Organizing Committee of SHARE. “ Medical, we tend to assume that if the patient does not reach its goals of blood pressure is due to their lack of adherence to treatment, but the survey shows clearly that health professionals also can do more to help our patients achieve their goals of hypertension ”, adds Professor Schmieder.

SHARE aims to understand the challenges faced by health workers in achieving their patients to achieve the proposed objectives of blood pressure. It is an initiative sponsored by European leaders in the field of hypertension with the support of Daiichi Sankyo. SHARE is part of HypertensionCare, the platform through which Daiichi Sankyo provides the occupational health services, knowledge and a broad range of medicines based on olmesartan, with the aim of contributing to effectively combat high blood pressure. For more information about SHARE and HypertensionCare.



about HypertensionCare.

HypertensionCare is the initiative of Daiichi Sankyo to high blood pressure that provides healthcare professionals a wide range of products, services and know-how in order to help them overcome the challenges posed by high pressure in their daily practice. HypertensionCare includes four drugs that offer a wide range of options to prevent the progression of hypertension: Olmetec ®, Olmetec Plus ®, Sevikar ® and Sevikar HCT ®, all of them based on olmesartan. addition products, Daiichi Sankyo provides health professionals with tools and training that allows them to learn more about obstacles which faced in achieving the levels proposed arterial pressure for their patients.



about Daiichi Sankyo.

the Group Daiichi Sankyo is dedicated to the research and supply of innovative pharmaceutical products, both in mature and emerging markets, that address various medical needs of patients who are not yet covered. The company was created in 2005 through the merger of two companies of Japanese tradition and Daiichi Sankyo. Daiichi Sankyo is one of the 20 leading pharmaceutical companies in the world. In addition to the maintenance of its drugs for hypertension, Hyperlipidemia, and bacterial infections, the group is focused on the development of treatments for disorders thrombotic research in Oncology as well as new therapies in the cardiovascular area and metabolism. On the other hand, Daiichi Sankyo group has created a “ hybrid business model “, which responds to the diversity of the market and customer seeking to optimize the opportunities for growth in the entire chain of value.

the company’s global headquarters is located in Tokyo. Its European base, Daiichi Sankyo Europe, is in Munich and has subsidiaries in 12 European countries as well as a plant of global manufacturing in Pfaffenhofen (Germany).



Read More

A simple analysis of urine allows preventing cardiovascular problems in treatment resistant hypertensive persons

|

a simple urine analysis allows to prevent cardiovascular problems in people with hypertension treatment-resistant

-A study led from the Mar Hospital demonstrates that the measure of the excretion of albumin in urine, marker of risk and prognosis of cardiovascular pathology directly associated with high blood pressure, may demonstrate a poor control of blood pressure, specifically during the night.

-the study raises a system of early detection of vascular damageeffective, simple, fast, non-invasive and economic, based on an analysis of urine and indicating the needing to step up treatment and prevention measures to avoid serious complications and consequences to patients, as well as costs to the system.

Barcelona, July of 2011. The team of hypertension and Vascular risk Mar Hospital Unit has done a study published in the prestigious journal Hypertension where it determines are the most useful parameters for assessing the presence of organic lesion and disease risk serious associated with high blood pressure. The findings of the study point to the numbers of nocturnal systolic blood pressure in combination with the measure of the excretion of albumin in urine may be markers of risk and prognosis of disease directly associated with high blood pressure.

Arterial hypertension is a major health problem around the world. It is estimated that there are more than 360 million of hypertensive patients. And the problems of the poor control of these figures of blood pressure, such as cardiovascular disease, the stroke, etc., can pose serious health problems. To treat asymptomatic disease and often go unnoticed, the perception of risk or illness by those who often suffer from is non-existent.

Good control of blood pressure figures is essential to avoid associated organic injury. An intermediate step is called subclinical organic lesion occurs prior to the emergence of organic lesion (infarction myocardium, advanced renal failure, etc.). It is essential to detect this first step towards effective measures that prevent, mitigate or minimize the effects of the established target organ injury. A good marker for this subclinical lesion is the microalbuminuria is more common in patients with hypertension resistant to treatment (20 per cent of the total of the hypertensive). There are groups of patients who, apparently, have a good control of blood pressure and that are not as resistant, but also presented microalbuminuria. In these cases, it is important to an ambulatory monitoring of blood pressure in 24 h, because it could be that day they were well controlled but not at night.

The complete study to detect the presence of subclinical lesion associated with hypertension includes many tests, explains the DRA. Resistant Anna Oliveras, clinical service Chief of Nephrology at Hospital del Mar, responsible for the hypertension and Vascular risk unit and one of the coordinators of the national registry of hypertensive “ analytical, EKG, ultrasound of the heart of the carotid arteries, knowing the speed of the pulse wavethe presence of renal failure, etc. and, in practice, make a very extensive study, is not possible everywhere ”. To detect so effective, simple, fast, non-invasive and economic this subclinical lesion facilitates the early detection of vascular damage, indicating the need to intensify the treatment and prevention measures to avoid serious complications and sequelae in patients, as well as costs to the system.

This study, conducted with a sample of more than 350 resistant hypertensive patients, has been made possible by the national registry of hypertension resistant of Spain, in the framework of the Spanish society of Arterial hypertension and determined by measuring the excretion of urine with a simple analysis of urine albumin (to be confirmed in)(at least 2 determinations), try non-invasive and economically, can improve the assessment of the risk of the patient. This, together with the determination of its nocturnal systolic pressure can facilitate a better assessment of the real cardiovascular risk associated with hypertension.

Resistant hypertensive are approximately 20% of the total, “ if we have in mind that by the year 2025 is estimated that there will be 60% more than hypertensive patients that currently and the figures will be close to 600 million patients affected around the world, the impact of the consequences of hypertension are of enormous significance ”, explains the DRA. Oliveras and concrete “ in Spain, 30% of the population has high pressure and the figure is almost double when we talk about patients 65 years or more. to provide reliable and economic tools to show us what patients are at risk of suffering serious organic disease of the hypertension andTherefore, what patients have a poor prognosis, it is essential in order to establish appropriate measures to mitigate and prevent the serious consequences of hypertension ”.

On the unity of hypertension

The Nephrology service of the Hospital of the sea has one of the units of hypertension for greater career and more consolidated in the Spain where are all the possible diagnostic and therapeutic techniques. One of the major areas of study is resistant hypertension. The DRA. Oliveras, responsible for the unit, is also coordinating with other professionals, the national registry of resistant hypertension.

Read More

The new President of the International Association of cardiac surgeons taught a course at the Dominican Republic.

|

The new President of the International Association of cardiac surgeons taught a course at Dominican Republic.

-Spanish doctor, Dr. Javier Cabo Salvador, President of the International Association of cardiac surgeons, Director of the masters in healthcare management from CEF and Director of the health area of the University to distance Madrid, will travel to Dominican Republic to provide, from 4 to 6 Julya course management Clinical Hospital at the Global Institute of higher studies in social sciences of the Dominican Republic. In addition, the teacher and Spanish doctor taught a paper under the title of “ heart transplant and Ventricular assistance ” on July 7 in the Universidad Central del Este (UCE).

Santo Domingo, Dominican Republic, 2011-July Between day 4 and 6 of the month of July, the school of business University distance of Madrid, UDIMA, and Spanish CEF taught a course in management Clinical Hospital at the Global Institute of higher studies in social science, in the city of Santo Domingo. This course will be taught by Dr. Javier Cabo Salvador, Chief clinical surgery Cardiovascular of the Hospital de La Paz (Madrid) and Director of the masters in healthcare management from the CEF. Also on July 7 after Dr. will give a presentation, under the title of “ heart transplant and Ventricular assistance ” in the East Central University, UCE, in San Pedro de Macorís.

The course

The course of management clinic hospital is aimed at those professionals, medical, managerial or political, the responsibility of managing a health service. Each, which combined the lectures given by Dr. Cape with the development of case studies and audiovisual presentations will span a total of 3 sessions of 5 hours.

The management clinic hospital course aims to convey to participants the need to learn how to manage a health service, the gap between needs and available resources. Therefore, this situation implies that those resources should be used in the best possible way to achieve the objectives set, forcing introduce economic concepts such as profitability, cost and benefit, equitable allocation of health resources, etc.

In the words of Dr. Javier Cape, director and principal teacher of this course, “ the hospital clinical management is one of the major challenges facing health systems around the world. A country can have the best doctors in the world but it will be totally inoperative from the health point of view if there is not an efficient system to support behind work that medical ”.

On the other hand, it is also expected on July 7 after Dr made a presentation under the title of “ heart transplant and Ventricular assistance ” in the Central University of the East. The paper will be directed to cardiac surgeons in the Dominican Republic and will focus on the latest techniques and discoveries associated with this complex field of cardiac surgery.

Dr. Javier Cabo

The classes in this course will be taught by Dr. Javier Cabo Salvador, Chief clinical surgery Cardiovascular of the Hospital de La Paz (Madrid) and Director of the masters in healthcare management from the CEF and the area of health of the UDIMA. It is also co-author and director of the book “ integrated health management – public and private ” (CEF editions).

Dr. Cape is a pioneer in surgery for arrhythmias Spain, to create the first unit of surgery of arrhythmias in pediatric age of Europe in 1989. In addition, conducted the first heart transplant in a newborn in Spain in May of 1994. In 2006 he carried out the first assistance biventricular Spain with an artificial heart and first in the world by associating an ECMO and assistance. On 18 June he was appointed President of the International Association of Cardiac Surgeons in Montreal.

About the CEF

CEF (Centro de Estudios Financieros) is a private training center and business pioneer in Spain school. With great tradition and prestige firmly consolidated in the educational and editorial panorama of our country, the CEF started in 1977. Since then it has developed various areas of first level training aimed at professionals in the public and private spheres. Its areas of activity include the preparation of oppositions, the masters and post-graduate, the training courses for companies and specialized publications. During his 34 years of existence more than 325,000 students have passed through its classrooms. The CEF is also the main promoter of the University to distance Madrid UDIMA.

Read More

Menarini launches Balzak Pplus ® for the treatment of high blood pressure.

|

Menarini launches Balzak Pplus ® for the treatment of hypertension blood.

Badalona, 2011-July the new antihypertensive Menarini group, Balzak Pplus ®, is a triple combination fixed dose of an ARA II (olmesartan medoxomilo), a calcioantagonista (maleate) and a diuretic (hydrochlorothiazide). Is indicated as replacement therapy in hypertensive adult patients as replacement therapy in casoscuya whose blood pressure estéá properly controlled adequately with the combination of olmesartan medoxomilo, maleate and hydrochlorothiazide, taken as a combination double (including olmesartan medoxomilo) along with a formulation of a single componente.con olmesartan medoxomilo with another combination of the components or taken both separately.

in a randomized, controlled, double blind study included 2,492 patients with hypertension of moderate gravesevera, lala triple combination provided a further reduction in both systolic and diastolic blood pressure as well as a greater patients númeroporcentaje than respondedoresalcanzaron the objectives of blood pressure with dual therapy even those sub-groups of patients of difficult to control: over 65s, diabetic, black and with metabolic syndrome. EAsimismo, the treatment offers better coverage for 24 hours by a single daily tomatoma that the respective dual therapies and in turn has been well tolerated in the different studies. Available in five different presentations to adapt to the needs of each paciente.fue generally tolerated, even in those difficult to control patient subgroups: the over 65s, diabetic, black and with syndrome metabolic

in Spain is currently estimated that only 40 percent of hypertensive patients are controlled, therapeutic failure to the patient to be one of the main causes of this under control. This is due, to a greater extent, to a third of the mismospacientes require three or more drugs to control hypertension sula, is therefore expected that useful combination to fixed-dose triple unala resultea…

, European guidelines of hypertension recommended the combination of an inhibitor of the Renin angiotensin ARA II system, a calcioantagonista and a loop diuretic such as combination of three drugs when necessary as well as the combinations to dose establishes sussus mechanisms of action are complementary and allow mejorarn effectiveness, the tolerability of treatment and compliance by the patient.

cardiovascular diseases are the leading cause of death in Spain and high blood pressure is the main factorfactor of cardiovascular risk and the most common in our country, with a prevalence of over 40 per cent in patients over the age of 35 years and 68 percent in people over 60. In addition, in the majority of hypertensive patients often padecercoexistir also as dyslipemias or diabetes, diseases that contribute to increasing the total cardiovascular risk of these pacientes.lo that converts to high blood pressure in a high risk factor cardiovascular.


research Menarini.

Menarini Group devoted much of his effort to innovation and the search for pharmaceutical products that meet the needs of society. In this regard, the Group has six r & d centres in Europe: four in Italy (Florence, Pomezia, Milan and Pisa), one in Germany (Berlin) and one in Spain (Badalona). Menarini in Spain Centre has as a priority line of research development of medication to fight the pain, inflammation and asthma, cardiovascular disease, disorders of gastrointestinal motility and viral skin infections.

Menarini is an international pharmaceutical group with 125 years of history that is present in more than 100 countries in Europe, Asia, Africa and America. In Spain, he started his career for 50 years and today employs 550 people in our country.


Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips